SUPERNUS PHARMACEUTICALS, INC. Proceeds from Convertible Debt
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2021-03-08
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2019-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2019-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2018-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2018-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2020 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2018 was $402.50M.
- SUPERNUS PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2017 was $0.00.
| Period end | Proceeds from Convertible Debt 0 month | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-08 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-08 | $0.00 10-K · filed 2021-03-08 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-09 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-08 | $0.00 derived: sum of 3 quarters · filed 2021-03-08 | $402.50M 10-K · filed 2021-03-08 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $402.50M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $402.50M 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $402.50M 10-Q · filed 2019-05-10 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 | ||||
| 2013-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $0.00 derived: sum of 2 quarters · filed 2017-01-20 | $86.50M derived: sum of 3 quarters · filed 2017-01-20 | $90.00M 10-K/A · filed 2017-01-20 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $86.50M derived: sum of 2 quarters · filed 2014-11-12 | $90.00M 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | $86.50M 10-Q · filed 2013-08-14 | $90.00M 10-Q · filed 2014-08-12 | |||
| 2013-05-03 | $86.50M 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |